SPY332.80-2.77 -0.83%
DIA277.19-0.95 -0.34%
IXIC10,782.82-185.53 -1.69%

Morgan Stanley Maintains Overweight on MyoKardia, Lowers Price Target to $70

Morgan Stanley maintains MyoKardia (NASDAQ:MYOK) with a Overweight and lowers the price target from $71 to $70.

Benzinga · -

Morgan Stanley maintains MyoKardia (NASDAQ:MYOK) with a Overweight and lowers the price target from $71 to $70.